In June 2024, the SPIOMET4HEALTH project celebrated its second review meeting, reaffirming its commitment to developing the first treatment for Polycystic Ovary Syndrome (PCOS) with strategic decisions to tackle future challenges and opportunities.
The meeting was attended online by the European Comission’s Project’s Officer and two external experts in the field, who joined representatives from all consortium partners. The session began with a warm welcome and introductions from the attendees, setting the stage for a day of productive discussions and decision-making around the ongoing clinical trial.
The agenda covered key aspects of the project’s progress and coordination. Discussions focused on updates from each work package, highlighting achievements, potential challenges, and risk mitigation strategies. The two external experts provided valuable insights for each work package, refining approaches and identifying new opportunities for project enhancement. Special emphasis was placed on the nearing completion of the recruitment period, with partners exploring various methods to enhance project outreach and engagement.
This gathering marked a significant step forward in the collaborative effort to drive innovation and research towards developing the first treatment specifically for Polycystic Ovary Syndrome (PCOS).
The session ensured alignment with project objectives and timelines, reaffirming the partners’ dedication to the project’s success. With strategic decisions made and actions agreed upon, the meeting concluded with a clear focus on addressing the challenges and opportunities ahead for the remainder of the project. All partners were thanked for their effort and encouraged to continue working to achieve the ambitious goals of the project.
Towards a solution for PCOS: clinical trial progress
Currently, the project team is actively recruiting patients for the clinical trial. SPIOMET4HEALTH is seeking participants aged 12 to 24 with PCOS, characterized by irregular menstrual periods and excess body hair, across several locations: Spain (Barcelona and Girona), Austria (Graz), Norway (Trondheim), Italy (Bologna), Denmark (Odense), and Turkey (Istanbul). All the information about how to participate can be found here.